PAS-004 Delivers Durable Clinical Activity, Long-Term Safety in Advanced Cancer Phase 1; Pasithea Expands Protocol
KTTA has more than doubled off its 52-week low of $0.281.
Summary
Pasithea Therapeutics announced positive interim Phase 1 data for its drug candidate PAS-004 in advanced cancer patients, demonstrating long-term safety, tolerability, and durable clinical activity. The data showed stable disease for over six months, with two patients on study for over one year, in heavily pre-treated patients who had failed prior MEK/BRAF inhibitor therapies, exceeding the typical 5-month progression-free survival in this setting. This positive outcome, coupled with a favorable safety profile, de-risks the asset and supports its potential as a differentiated MEK inhibitor. The company is expanding the protocol to explore higher dose levels and initiate a pilot food effect study, indicating confidence in further development. This builds on recent positive developments for PAS-004, including Orphan Drug Designation in early June and a strong cash balance reported in May.
At the time of this announcement, KTTA was trading at $0.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.6M. The 52-week trading range was $0.28 to $2.06. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.